Sustained-release naltrexone/bupropion-a novel pharmacologic approach to obesity and food craving

US Endocrinology

Volumn 10, Issue 1, 2014, Pages 53-58

  Fujioka, Ken ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Bupropion; Craving; Feeding behavior; Naltrexone; Obesity; Reward; Weight loss

Indexed keywords

EID: 84906965115     PISSN: 17583918     EISSN: 17583926     Source Type: Journal    
DOI: 10.17925/use.2014.10.01.53     Document Type: Article

References (72)

1. Narkiewicz K, Obesity and hypertension-the issue is more complex than we thought, Nephrol Dial Transplant, 2006;21:264-7
2. Wilson PW, D'Agostino RB, Sullivan L, et al., Overweight and obesity as determinants of cardiovascular risk: the Framingham experience, Arch Intern Med, 2002;162:1867-72.
3. Rodbard HW, Bays HE, Gavin JR, 3rd, et al., Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study, Int J Clin Pract, 2012;66:684-91.
4. Chan JM, Rimm EB, Colditz GA, et al., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men, Diabetes Care, 1994;17:961-9.
5. Katsiki N, Ntaios G, Vemmos K, Stroke, obesity and gender: a review of the literature, Maturitas, 2011;69:239-43
6. Renehan AG, Tyson M, Egger M, et al., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008;371:569-78.
7. Anandacoomarasamy A, Caterson ID, Leibman S, et al., Influence of BMI on health-related quality of life: comparison between an obese adult cohort and age-matched population norms, Obesity (Silver Spring), 2009;17:2114-8.
8. Olshansky SJ, Passaro DJ, Hershow RC, et al., A potential decline in life expectancy in the United States in the 21st century, N Engl J Med, 2005;352:1138-45.
9. Wang YC, McPherson K, Marsh T, et al., Health and economic burden of the projected obesity trends in the USA and the UK, Lancet, 2011;378:815-25.
10. Finkelstein EA, Khavjou OA, Thompson H, et al., Obesity and severe obesity forecasts through 2030, Am J Prev Med, 2012;42:563-70.
11. Miller ER, 3rd, Erlinger TP, Young DR, et al., Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT), Hypertension, 2002;40:612-8.
12. Pi-Sunyer FX, A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity, Clin Ther, 1996;18:1006-35; discussion 5
13. Plourde G, Treating obesity. Lost cause or new opportunity? Can Fam Physician, 2000;46:1806-13.
14. Case CC, Jones PH, Nelson K, et al., Impact of weight loss on the metabolic syndrome, Diabetes Obes Metab, 2002;4:407-14.
15. Truong KD, Sturm R, Weight gain trends across sociodemographic groups in the United States, Am J Public Health, 2005;95:1602-6
16. Cohen DA, Neurophysiological pathways to obesity: below awareness and beyond individual control, Diabetes, 2008;57:1768-73
17. Cone RD, Anatomy and regulation of the central melanocortin system, Nat Neurosci, 2005;8:571-8
18. Cowley MA, Cone R, Enriori P, et al., Electrophysiological actions of peripheral hormones on melanocortin neurons, Ann N Y Acad Sci, 2003;994:175-86.
19. Morton GJ, Cummings DE, Baskin DG, et al., Central nervous system control of food intake and body weight, Nature, 2006;443:289-95.
20. Saper CB, Chou TC, Elmquist JK, The need to feed: homeostatic and hedonic control of eating, Neuron, 2002;36:199-211
21. Reece AS, Hypothalamic opioid-melanocortin appetitive balance and addictive craving, Med Hypotheses, 2011;76:132-7
22. Pandit R, de Jong JW, Vanderschuren LJ, et al., Neurobiology of overeating and obesity: the role of melanocortins and beyond, Eur J Pharmacol, 2011;660:28-42.
23. Berridge KC, The debate over dopamine's role in reward: the case for incentive salience, Psychopharmacology (Berl), 2007;191:391-431
24. Kelley AE, Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning, Neurosci Biobehav Rev, 2004;27:765-76
25. Olszewski PK, Shaw TJ, Grace MK, et al., Complexity of neural mechanisms underlying overconsumption of sugar in scheduled feeding: involvement of opioids, orexin, oxytocin and NPY, Peptides, 2009;30:226-33.
26. Levine AS, Billington CJ, Opioids as agents of reward-related feeding: a consideration of the evidence, Physiol Behav, 2004;82:57-61
27. Kelley AE, Bakshi VP, Haber SN, et al., Opioid modulation of taste hedonics within the ventral striatum, Physiol Behav, 2002;76:365-77.
28. Zheng H, Patterson LM, Berthoud HR, Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens, J Neurosci, 2007;27:11075-82
29. Kirkham TC, Endocannabinoids and the non-homeostatic control of appetite, Curr Top Behav Neurosci, 2009;1:231-53
30. Fujioka K, Burns C, Walsh B, et al., Early improvement in control of eating is associated with long-term weight loss - integrated analysis of four phase 3 trials of combination naltrexone/ bupropion treatment. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013; Chicago, IL, US; abstract no 1149-P, 2013.
31. Stice E, Spoor S, Ng J, et al., Relation of obesity to consummatory and anticipatory food reward, Physiol Behav, 2009;97:551-60.
32. Small DM, Individual differences in the neurophysiology of reward and the obesity epidemic, Int J Obes (Lond), 2009;33(Suppl. 2):S44-8.
33. Jastreboff AM, Sinha R, Lacadie C, et al., Neural correlates of stress- and food cue-induced food craving in obesity: association with insulin levels, Diabetes Care, 2013;36:394-402.
34. Martin LE, Holsen LM, Chambers RJ, et al., Neural mechanisms associated with food motivation in obese and healthy weight adults, Obesity (Silver Spring), 2010;18:254-60.
35. Stice E, Spoor S, Bohon C, et al., Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study, J Abnorm Psychol, 2008;117:924-35.
36. Del Parigi A, Gautier JF, Chen K, et al., Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography, Ann N Y Acad Sci, 2002;967:389-97.
37. Volkow ND, Wang GJ, Baler RD, Reward, dopamine and the control of food intake: implications for obesity, Trends Cogn Sci, 2011;15:37-46
38. Rothemund Y, Preuschhof C, Bohner G, et al., Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals, Neuroimage, 2007;37:410-21.
39. Stoeckel LE, Weller RE, Cook EW, 3rd, et al., Widespread rewardsystem activation in obese women in response to pictures of high-calorie foods, Neuroimage, 2008;41:636-47.
40. Del Parigi A, Chen K, Salbe AD, et al., Persistence of abnormal neural responses to a meal in postobese individuals, Int J Obes Relat Metab Disord, 2004;28:370-7.
41. Hinkle W, Cordell M, Leibel R, et al., Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans, PLoS One, 2013;8:e59114.
42. Chechlacz M, Rotshtein P, Klamer S, et al., Diabetes dietary management alters responses to food pictures in brain regions associated with motivation and emotion: a functional magnetic resonance imaging study, Diabetologia, 2009;52:524-33.
43. Billes SK, Greenway FL, Combination therapy with naltrexone and bupropion for obesity, Expert Opin Pharmacother, 2011;12:1813-26
44. Bouza C, Angeles M, Munoz A, et al., Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction, 2004;99:811-28.
45. Gadde KM, Xiong GL, Bupropion for weight reduction, Expert Rev Neurother, 2007;7:17-24
46. Billes SK, Cowley MA, Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice, Neuropsychopharmacology, 2007;32:822-34
47. Anderson JW, Greenway FL, Fujioka K, et al., Bupropion SR enhances weight loss: a 48-week double-blind, placebocontrolled trial, Obes Res, 2002;10:633-41.
48. Jain AK, Kaplan RA, Gadde KM, et al., Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms, Obes Res, 2002;10:1049-56.
49. Gadde KM, Parker CB, Maner LG, et al., Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women, Obes Res, 2001;9:544-51.
50. Greenway FL, Whitehouse MJ, Guttadauria M, et al., Rational design of a combination medication for the treatment of obesity, Obesity (Silver Spring), 2009;17:30-9.
51. Giuliano C, Robbins TW, Nathan PJ, et al., Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating, Neuropsychopharmacology, 2012;37:2643-52.
52. Taber MT, Zernig G, Fibiger HC, Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens, Brain Res, 1998;785:24-30
53. Maggio CA, Presta E, Bracco EF, et al., Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men, Brain Res Bull, 1985;14:657-61.
54. Malcolm R, O'Neil PM, Sexauer JD, et al., A controlled trial of naltrexone in obese humans, Int J Obes, 1985;9:347-53.
55. Billes SK, Sinnayah P, Cowley MA, Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss, Pharmacol Res, 2014;84C:1-11
56. Sinnayah P, Wallingford NM, Evans AE, et al., Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 2007;15:A179.
57. Greenway FL, Dunayevich E, Tollefson G, et al., Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo, J Clin Endocrinol Metab, 2009;94:4898-906.
58. Greenway FL, Fujioka K, Plodkowski RA, et al., Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2010;376:595-605.
59. Wadden TA, Foreyt JP, Foster GD, et al., Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial, Obesity (Silver Spring), 2011;19:110-20.
60. Apovian CM, Aronne L, Rubino D, et al., A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity (Silver Spring), 2013;21:935-43.
61. Hollander P, Gupta AK, Plodkowski R, et al., Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes, Diabetes Care, 2013;36:4022-9.
62. Kenkre J, Tan T, Bloom S, Treating the obese diabetic, Expert Rev Clin Pharmacol, 2013;6:171-83
63. Kolotkin RL, Burns C, Walsh B, et al., Combination naltrexone/ bupropion therapy resulted in clinically meaningful improvements in weight and quality of life (QoL) - integrated analysis of four Phase 3 trials; presented at the American Diabetes Association 73rd Scientific Session, June 21-25; Chicago, IL, US; abstract no 2013-A-2723.
64. Flint A, Raben A, Blundell JE, et al., Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies, Int J Obes Relat Metab Disord, 2000;24:38-48.
65. Wang GJ, Tomasi D, Volkow ND, et al., Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues, Int J Obes (Lond), 2014;38:682-8.
66. Apovian C, Burns C, Walsh B, et al., An integrated analysis of weight loss with combination naltrexone/bupropion therapy by BMI (abesity) classification; presented at the American Diabetes Association 73rd scientific session, June 21-25, 2013, Chicago, IL, US; abstract no 1013-A-273B.
67. GSK, Wellbutrin; highlights of prescribing information. Available at: http://www.gsksource.com/gskprm/htdocs/documents/WELLBUTRIN-SR-PI-MG.PDF (accessed April 30, 2014).
68. http://clinicaltrials.gov/ct2/show/NCT01601704?term=contrave&rank=3, Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study). Available at: http://clinicaltrials.gov/ct2/show/NCT01601704?term=contrave&rank=3 (accessed March 19, 2014).
69. Orexigen, Orexigen announces successful interim analysis of contrave Light Study, 25 Nov 2013. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irolnewsArticle&ID=1879629&highlight= (accessed March 20, 2014).
70. Wilcox CS, Oskooilar N, Erickson JS, et al., An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects, Addict Behav, 2010;35:229-34.
71. McElroy SL, Guerdjikova AI, Kim DD, et al., Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study, Prim Care Companion CNS Disord, 2013;15(3). pii: PCC.12m01494.
72. Smith SR, Fujioka K, Gupta AK, et al., Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity, Diabetes Obes Metab, 2013;15:863-6.